Concepedia

Publication | Closed Access

Phase I Clinical Trial of Intravenous L-ascorbic Acid Following Salvage Chemotherapy for Relapsed B-cell non-Hodgkin's Lymphoma.

17

Citations

22

References

2014

Year

Hiroshi Kawada, Masakazu Sawanobori, Mitsuyo Tsuma-Kaneko, Izumi Wasada, Mitsuki Miyamoto, Hiromichi Murayama, Masako Toyosaki, Makoto Onizuka, Kosuke Tsuboi, Kei Tazume,
PubMed

Abstract

Intravenous AA at a whole body dose of 75 g appears to be safe and sufficient to achieve an effective serum concentration. A phase II trial to evaluate the efficacy of intravenous AA in relapsed/refractory lymphoma patients will now be initiated.

References

YearCitations

Page 1